Long Non-Coding RNA IGFRIL Couples with PTBP1 to Destabilize IGFBP3 mRNA to Promote the IGF1R-AKT-mTOR Axis and...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Incomplete understanding of Insulin-like Growth Factor Receptor (IGFR) pathway activation limits hepatocellular carcinoma (HCC) treatment.
• Identification of novel molecular targets is crucial for advancing HCC therapy.

Purpose of the Study:

• To identify novel hepatocellular carcinoma (HCC)-associated long non-coding RNAs (lncRNAs).
• To elucidate the mechanism by which a newly identified lncRNA, IGFRIL, contributes to HCC development.
• To evaluate IGFRIL as a potential therapeutic target for HCC.

Main Methods:

• Transcriptome-wide screening to identify HCC-associated lncRNAs.
• In vitro assays to determine the functional role and mechanism of IGFRIL in HCC.
• Analysis of IGFRIL expression in HCC tissues and correlation with clinical outcomes.
• In vivo studies using patient-derived tumor xenografts to assess therapeutic efficacy.

Main Results:

• A novel lncRNA, IGFRIL, was identified and found to be frequently upregulated in HCC tissues.
• IGFRIL promotes HCC development by acting as a scaffold for PTBP1, leading to IGFBP3 mRNA destabilization and IGF1R-AKT-mTOR pathway overactivation.
• High IGFRIL expression predicts poor clinical outcomes in HCC patients.
• IGF1R or mTOR inhibitors suppressed tumor growth in patient-derived xenografts with high IGFRIL expression.

Conclusions:

• IGFRIL is a novel non-coding activator of the IGF1R pathway in hepatocellular carcinoma (HCC).
• IGFRIL plays a significant oncogenic role in HCC development and progression.
• IGFRIL represents a promising new therapeutic target for HCC patients, with inhibitors of the IGF1R-AKT-mTOR pathway showing efficacy.